Mean residence time for drugs subject to enterohepatic cycling. 1989

T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
College of Pharmacy, Rutgers University, Piscataway, New Jersey 08855-0789.

A physiologically realistic model of enterohepatic cycling (EHC) which includes separate liver and gallbladder compartments, discontinuous gallbladder emptying and first-order absorption from both an oral formulation and secreted bile (kapo and kab, respectively) has been developed. The effect of EHC on area under the first-moment curve (AUMC) of drug concentration in plasma and on parameters derived from the AUMC was investigated. Unlike AUC, AUMC is dependent on the time and time-course of gallbladder emptying, increasing as the interval between gallbladder emptying increases. Consequently, mean residence time (MRT) is also a time-dependent parameter. Analytical solutions for MRTiv and MRTpo were derived. Mean absorption time (MAT = MRTpo - MRTiv) is also time-dependent, contrary to findings previously published for a model of EHC with a continuous time lag. MAT is also dependent on kapo, kba and the hepatic extraction ratio. The difference between MRTpos for two formulations with unequal kapo values may deviate from the difference in the inverse of their absorption rate constants. Implications for design and interpretation of pharmacokinetic studies include (i) MAT values may be dominated by the time-course of recycling rather than the time-course of the initial absorption, depending on the extent of EHC and (ii) the unpredictable nature of the time of gallbladder emptying will contribute to intrasubject variability in derived parameters during crossover studies. Knowledge of the extent of EHC is invaluable in deciding whether modification of the in vitro release characteristics of an oral formulation will have any effect on the overall time-course of absorption in vivo. Techniques to monitor or control gallbladder emptying may be helpful for reducing variability in pharmacokinetic studies for compounds which are extensively cycled in bile.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010599 Pharmacokinetics Dynamic and kinetic mechanisms of exogenous chemical DRUG LIBERATION; ABSORPTION; BIOLOGICAL TRANSPORT; TISSUE DISTRIBUTION; BIOTRANSFORMATION; elimination; and DRUG TOXICITY as a function of dosage, and rate of METABOLISM. LADMER, ADME and ADMET are abbreviations for liberation, absorption, distribution, metabolism, elimination, and toxicology. ADME,ADME-Tox,ADMET,Absorption, Distribution, Metabolism, Elimination, and Toxicology,Absorption, Distribution, Metabolism, and Elimination,Drug Kinetics,Kinetics, Drug,LADMER,Liberation, Absorption, Distribution, Metabolism, Elimination, and Response
D004764 Enterohepatic Circulation Recycling through liver by excretion in bile, reabsorption from intestines (INTESTINAL REABSORPTION) into portal circulation, passage back into liver, and re-excretion in bile. Circulation, Enterohepatic,Entero-Hepatic Circulation,Circulation, Entero-Hepatic,Circulations, Entero-Hepatic,Circulations, Enterohepatic,Entero Hepatic Circulation,Entero-Hepatic Circulations,Enterohepatic Circulations
D005704 Gallbladder A storage reservoir for BILE secretion. Gallbladder allows the delivery of bile acids at a high concentration and in a controlled manner, via the CYSTIC DUCT to the DUODENUM, for degradation of dietary lipid. Gallbladders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
July 1987, The Journal of pharmacy and pharmacology,
T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
December 1985, Journal of pharmacokinetics and biopharmaceutics,
T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
February 1985, Journal of pharmaceutical sciences,
T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
March 1982, Journal of pharmaceutical sciences,
T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
June 1979, Journal of pharmaceutical sciences,
T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
May 1986, Methods and findings in experimental and clinical pharmacology,
T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
July 1986, Experimental and clinical endocrinology,
T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
July 1985, Journal of pharmaceutical sciences,
T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
February 1988, Die Pharmazie,
T A Shepard, and G F Lockwood, and L J Aarons, and I D Abrahams
October 1985, Journal of pharmacokinetics and biopharmaceutics,
Copied contents to your clipboard!